Scarica l'app Stockscreener
1.25
2.34%
-0.03
Dopo l'orario di chiusura:
1.31
0.06
+4.80%
Precedente Chiudi:
$1.28
Aprire:
$1.28
Volume 24 ore:
114.84K
Relative Volume:
0.88
Capitalizzazione di mercato:
$85.97M
Reddito:
-
Utile/perdita netta:
$-9.22M
Rapporto P/E:
-4.2852
EPS:
-0.2917
Flusso di cassa netto:
$-4.60M
1 W Prestazione:
+0.81%
1M Prestazione:
-0.79%
6M Prestazione:
-7.41%
1 anno Prestazione:
-32.80%
Intervallo 1D:
$1.25
$1.35
Intervallo di 1 settimana:
$1.23
$1.35
Portata 52W:
$1.05
$3.10
Telomir Pharmaceuticals Inc Stock (TELO) Company Profile
Nome
Telomir Pharmaceuticals Inc
Settore
Industria
Telefono
786-396-6723
Indirizzo
100 SE 2ND ST, MIAMI
Compare TELO vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TELO
Telomir Pharmaceuticals Inc
|
1.25 | 88.72M | 0 | -9.22M | -4.60M | -0.2917 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Telomir Pharmaceuticals Inc Stock (TELO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-21 | Iniziato | Rodman & Renshaw | Buy |
Telomir Pharmaceuticals Inc Borsa (TELO) Ultime notizie
Telomir Pharmaceuticals, Inc.: Telomir-Zn reverses insulin resistance in 14 days in new study - Traders Union
Exclusive: Telomir Pharmaceuticals secures FDA nod for its breast cancer therapy to advance into human study - MSN
Telomir Showcases Preclinical Telomir-Zn Diabetes Efficacy Data - TipRanks
Telomir Pharmaceuticals Publishes Peer-Reviewed Data Showing Telomir-Zn Restores Insulin Sensitivity in Type 2 Diabetes Model – Minichart - Minichart
Telomir publishes preclinical data on diabetes treatment candidate - Investing.com
Telomir publishes preclinical data on diabetes treatment candidate By Investing.com - Investing.com Canada
Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model - ACCESS Newswire
Telomir (NASDAQ: TELO) adds Telomir-Zn diabetes data to support FDA-cleared TNBC trial - Stock Titan
Experimental drug candidate reversed insulin resistance in 14 days — in fish - Stock Titan
Telomir Pharmaceuticals (TELO) Q4 2025 Earnings: Wider-than-Expected Loss Highlights Pre‑Revenue Development StageSubscription Growth Report - newsline.com
Telomir Pharmaceuticals, Inc. reveals promising anti-tumor impact with Telomir-Zn in prostate cancer study - Traders Union
Telomir Pharmaceuticals (TELO) CFO Andriy Mushak files initial Form 3 - Stock Titan
Telomir Pharmaceuticals appoints Andriy Mushak as fractional CFO - Investing.com UK
Telomir Pharmaceuticals Appoints Fractional CFO After Leadership Change - TipRanks
Telomir Pharmaceuticals appoints Andriy Mushak as fractional CFO By Investing.com - Investing.com South Africa
Telomir PharmaceuticalsAlan Weichselbaum To Step Down As CFO Effective June 6, 2026SEC Filing - TradingView
Telomir Pharmaceuticals, Inc. Announces CFO Changes, Effective June 6, 2026 - marketscreener.com
Telomir Pharmaceuticals (NASDAQ: TELO) taps consultant as new fractional CFO - Stock Titan
Telomir Pharmaceuticals (TELO) Edges Lower Amid Consolidation Near SupportTrend Following Picks - newsline.com
Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer - ACCESS Newswire
TELO Stock Price, Quote & Chart | TELOMIR PHARMACEUTICALS INC (NASDAQ:TELO) - ChartMill
Telomir Pharmaceuticals (TELO) Edges Lower, Testing Support Levels Amid Low VolumeProfitability Factor - The Legal Advocate
TELO Q4 2025 Earnings: EPS Misses Estimates by 292% as Cash Burn Continues; No Revenue ReportedEPS Surprise History - newsline.com
Telomir Pharmaceuticals (TELO) Consolidates Near $1.29 as Support and Resistance Levels TightenATR Stop - The Legal Advocate
Telomir Pharmaceuticals Inc. (TELO) Q4 2025 Earnings: Significant EPS Miss Amid Pre-Clinical Stage OperationsNext Quarter Guidance - The Legal Advocate
Telomir Pharmaceuticals Inc. (TELO) Q4 2025 Earnings: Wider Than Expected Loss Highlights Pre-Revenue ChallengesCFO Commentary Report - The Legal Advocate
Telomir Pharmaceuticals Q4 2025 Earnings: Wider Than Expected Loss Highlights Clinical-Stage ChallengesAnnual Financial Report - newsline.com
Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer - ACCESS Newswire
Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn) - ACCESS Newswire
Telomir Pharmaceuticals Inc. (TELO) Q4 2025 Earnings: Wider-than-Expected Loss Highlights Development-Stage ChallengesReturn On Capital - The Legal Advocate
Telomir Pharmaceuticals (TELO) director swaps 25K options for lower $1.30 strike - Stock Titan
Telomir Pharmaceuticals (TELO) director resets 25K stock options terms - Stock Titan
Telomir Pharmaceuticals Q4 2025 Earnings: Wider-than-Expected Loss as Revenue Remains AbsentRising Community Picks - Newser
Telomir (NASDAQ: TELO) CEO reshapes 4M+ options at lower $1.30 strike - Stock Titan
Telomir Pharmaceuticals (TELO) Stock Analysis: -4.96% Down — Bearish Signals to Watch 2026-05-21Smart Money Flow Stocks - Newser
Telomir Pharmaceuticals (TELO) Q4 2025 Miss: What Went WrongQuarterly Financial Update - The Legal Advocate
Telomir Pharmaceuticals Publishes Peer-Reviewed Data Showing Telomir-Zn Improves Survival and Liver Outcomes in Wilson’s Disease Model - Minichart
Telomir Pharmaceuticals publishes peer-reviewed study on Telomir-Zn for Wilson disease - Traders Union
Telomir-Zn Preclinical Data Published in Wilson’s Disease - TipRanks
Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease - ACCESS Newswire
Wilson’s disease study backs Telomir-Zn for Telomir (NASDAQ: TELO) - Stock Titan
Study links Telomir-Zn to better survival in toxic copper buildup disorder - Stock Titan
Telomir Pharmaceuticals (TELO) Q4 2025 Disappoints — EPS $-0.28 Below $-0.07 ViewsEBITDA Margin Trends - Newser
Telomir Pharmaceuticals, Inc. 1Q 2026: Revenue $0 EPS $(0.03) — 10-Q Summary - TradingView
Telomir (NASDAQ: TELO) closes TELI deal amid Q1 loss and cash risk - Stock Titan
MIRA Pharmaceuticals (MIRA) posts Q1 2026 loss and warns on going concern - Stock Titan
TradingKey - TradingKey
GLP safety trials find Telomir 1 well tolerated, Telomir Pharmaceuticals, Inc. asserts - Traders Union
EXCLUSIVE: Telomir Pharmaceuticals Secures FDA Nod For Its Breast Cancer Therapy To Advance Into Human Study - Sahm
Telomir Pharmaceuticals Receives FDA Clearance for IND of Telomir-Zn in Phase 1/2 Trial for Triple-Negative Breast Cancer 8 - Minichart
Telomir Says US FDA Clears Investigational New Drug Application for Telomir-Zn to Treat Triple-Negative Breast Cancer - marketscreener.com
Telomir Pharmaceuticals Inc Azioni (TELO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.60%
0.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):